BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kis B, Lücke C, Abdel-Hamid M, Heßmann P, Graf E, Berger M, Matthies S, Borel P, Sobanski E, Alm B, Rösler M, Retz W, Jacob C, Colla M, Huss M, Jans T, van Elst LT, Müller HHO, Philipsen A. Safety Profile of Methylphenidate Under Long-Term Treatment in Adult ADHD Patients - Results of the COMPAS Study. Pharmacopsychiatry 2020;53:263-71. [PMID: 33017854 DOI: 10.1055/a-1207-9851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jaeschke RR, Sujkowska E, Sowa-Kućma M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review. Psychopharmacology (Berl) 2021;238:2667-91. [PMID: 34436651 DOI: 10.1007/s00213-021-05946-0] [Reference Citation Analysis]
2 Li DJ, Chen YL, Hsiao RC, Chen HL, Yen CF. Risk of Respiratory Infectious Diseases and the Role of Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder: A Population-Based Cohort Study. Int J Environ Res Public Health 2021;18:5824. [PMID: 34071586 DOI: 10.3390/ijerph18115824] [Reference Citation Analysis]